Con il tuo consenso utilizziamo analisi limitate e rispettose della privacy per capire quali percorsi di ricerca funzionano. Non usiamo tracker pubblicitari né registrazioni delle sessioni. Puoi modificare questa scelta nelle Preferenze. Leggi la Informativa sulla privacy.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
SYK — frequently asked questions
Is Stryker Corporation overvalued?
In our latest published analysis dated 2026-10-22, SYK looks modestly undervalued. The price recorded at analysis is 298 USD versus our fair value of 313 USD; the high endpoint is presented separately as potential value of 413 USD. That implies roughly 5.2% upside to fair value at that date.
Our latest published report, analyzed 2026-10-22, gives SYK a fair value of 313 USD and a potential value of 413 USD. The conclusion is triangulated across multiple valuation models and weighted by reliability for Stryker Corporation's archetype; it is a dated research output, not a live price.
Should I buy SYK now?
Our latest published rating for SYK, analyzed 2026-10-22, is Hold. Stryker Corporation looks modestly undervalued at the analysis-date price of 298 USD versus fair value of 313 USD; potential value is 413 USD. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for SYK?
The dedicated bear-case section in our report analyzed 2026-10-22 documents Stryker Corporation's material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is SYK's rating?
Our latest published rating for SYK, analyzed 2026-10-22, is Hold, with a published moat assessment of 8.5/10 (Narrow). It reflects our fair value of 313 USD, the potential value of 413 USD, and the price recorded at analysis (298 USD).
Questo report non è ancora stato tradotto. Aggiorna tra qualche minuto una volta che la coda di traduzione avrà recuperato.
§1 SintesiEN
Risposta in 30 secondiHold
Prezzo rispetto al valore
Prezzo
$297.60
Fair value
$313.18
Valore potenziale
$413.44
Al
2026-10-21
Perché può funzionare
Accelerated global Mako robotic penetration across inpatient hospitals and outpatient Ambulatory Surgery Centers, driving proprietary knee and hip implant pull-through and expanding international revenue beyond the current 24.3% non-U.S.
Cosa cambierebbe la nostra valutazione
A macroeconomic contraction or hospital budgetary austerity leading to deferred capital equipment commitments and delayed Mako placements.
Stryker Corporation (NYSE: SYK) carries a Hold rating with a fair value of $313.18, reflecting balanced risk-reward as strong procedural demand and robotic surgical leadership are counterbalanced by full valuation at $297.60 and transient operational overhead.4
Stryker Corporation has demonstrated operational resilience following first-quarter cyber and manufacturing disruptions, delivering healthy procedural demand across core reconstructive and endoscopy lines. Management has narrowed its full-year guidance corridor, projecting organic net sales growth between 8.3% and 9.3% and adjusted diluted earnings per share of $14.95 to $15.10. Expanding operating cash generation and disciplined capital allocation continue to reinforce the business model's durability.
While Stryker's competitive position in robotic surgery and hospital infrastructure remains entrenched, current market pricing reflects much of this operating recovery. Trading at $297.60, shares offer an implied return of +5.24% relative to the committee's $313.18 fair value midpoint. With valuation multiples elevated relative to medical device peers (such as BSX at 13.18x forward P/E and GEHC at 12.98x) and macroeconomic interest rates sustained at 5.15%, the committee maintains a Hold rating pending a wider margin of safety.2,3,4
Looking forward, execution will center on clearing acute Peripheral Vascular backorders by the end of Q3, converting elevated Mako robotic and smart bed backlogs into revenue, and managing a seamless executive transition to incoming CEO Spencer Stiles on January 1, 2027. Investors should maintain existing holdings while waiting for valuation pullbacks to add exposure.5
Robotic Orthopedic Moat and Sticky Consumable Pull-Through
Stryker's Mako system continues to set placement records across hospitals and ASCs, driving recurring, high-margin sales of proprietary knee and hip implants that solidify surgeon loyalty.5
As transient cyber remediation expenses and manufacturing absorption drag subside, operating leverage and efficiency initiatives are poised to drive multi-year adjusted operating margin expansion across both MedSurg and Orthopaedics.5
Stryker converted $5,044M in operating cash flow into $4,283M in free cash flow in FY2025, enabling programmatic bolt-on M&A, consistent dividend growth, and opportunistic share buybacks.5,6,7
Raccomandazione interna
Hold. Stryker is a best-in-class medtech compounder with widening competitive moats in robotic surgery, but current market pricing leaves valuation balanced against fundamental intrinsic value.
Panoramica dell’azienda
Stryker Corporation is a global medical technology company delivering innovative solutions across MedSurg and Neurotechnology as well as Orthopaedics. In FY2025, Stryker generated $25,116M in net sales, comprising $15,647M from MedSurg and Neurotechnology and $9,469M from Orthopaedics. Geographically, the United States accounted for $19,006M (75.7%) of net sales while international markets generated $6,110M (24.3%).
The company's diverse commercial portfolio includes joint replacement implants, surgical power tools, advanced endoscopy systems, neurosurgical devices, patient handling equipment, and connected clinical software, serving healthcare providers worldwide. Stryker announced that executive Spencer Stiles will succeed Kevin Lobo as Chief Executive Officer, with Lobo transitioning to Executive Chair of the Board.
§2 Scenario ribassistaEN
Under a combined macroeconomic slowdown and hospital capex freeze, capital equipment commitments are deferred and hospital procedural volumes soften. In this stress scenario, organic net sales growth slows below 4.0%, manufacturing fixed costs and elevated IT security overhead depress operating margins below 16.5%, and valuation multiples compress toward the peer medtech range of 13.0x-14.0x forward earnings, severely impairing intrinsic economic value.
Stryker Corporation possesses a Narrow economic moat founded on high customer switching costs, extensive operating room distribution scale, and an integrated clinical technology portfolio. The company's crown jewel is its Mako robotic-assisted orthopedic surgery system, which has established an industry-leading installed base that drives recurring sales of proprietary implants across total knee, partial knee, and total hip procedures. Hospital systems and surgeons invest heavily in robotic capital, software configuration, and surgical technique training, creating friction that disincentivizes switching to competing robotic platforms.
Complementing its orthopedic leadership, Stryker's MedSurg and Neurotechnology businesses command dominant market shares in surgical instruments, endoscopy, emergency care, and hospital infrastructure. By bundling capital equipment such as ProCuity smart beds with clinical workflow software from Vocera and Care.ai, Stryker embeds itself deeply into hospital enterprise procurement workflows, securing recurring consumable demand and reinforcing pricing stability even amidst broader healthcare budgeting pressures.
Profitto economico
Stryker generates returns well in excess of its cost of capital. In FY2025, operating profit of $4,889M on $25,116M revenue and an invested capital base of $38,279M supported a return on invested capital of 11.45%. This exceeds the company's weighted average cost of capital of 8.21% and moderate cost of equity of 8.64%, confirming persistent economic profit creation.2,6,7
8.5/ 10
Narrow
Sources of advantage
01High Customer Switching Costs in Robotic Surgery Ecosystem — Stryker's Mako robotic-arm platform deeply embeds proprietary Triathlon knee and hip implants into hospital surgical workflows and orthopedic surgeon practice, generating exceptionally high switching costs and reliable high-margin consumable implant pull-through.Wide
02Dominant Operating Room Distribution Scale and Portfolio Breadth — With FY2025 revenue of $15,647M in MedSurg and Neurotechnology and $9,469M in Orthopaedics, Stryker possesses an expansive commercial sales and service infrastructure that creates high barriers to entry and strong cross-selling leverage across hospital procurement departments.Wide
Hospital capital budget freezes and placement delays for major capital equipment
medium
12-18 months
Offering flexible acquisition models, expanding penetration into high-growth Ambulatory Surgery Centers, and relying on recurring procedural implant demand that insulates against purely capital freezes.
The highlighted cell is Fair value when every assumption sits at its base level ($313.18). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $3.6B after modeled reinvestment of $895.4M, with terminal value at 79.7% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.
EPS annual compound growth of 12.5% through explicit forecast horizon.
Adjusted operating margin expands beyond 21.2% ahead of schedule.
Rapid ASC robotic placement acceleration and sustained procedure volume expansion.5
Accelerated hospital capital equipment spending, record Mako robotic placements in hospital and ASC settings, and rapid clearance of Peripheral Vascular backorders drive double-digit earnings compounding and accelerated operating margin expansion ahead of house expectations.5
FY2026 revenue of $27.17B and adjusted EPS of $14.95.
§7 Albero decisionale degli utiliEN
Superato
Upgrade the rating; Re-evaluate capital allocation weighting, assess ASC order fulfillment acceleration, and review whether manufacturing capacity can absorb higher multi-year backlog without cost inflation.
Trigger: Organic net sales growth > 9.3% YoY and full-year adjusted EPS > $15.10 with operating margins expanding above 20.5%.5
Delivering results above the high end of organic sales guidance alongside robust margin recovery would prove that Mako adoption and operating leverage are running ahead of house expectations, justifying a positive rating revision.
In linea
Maintain Hold; Maintain current portfolio weighting, verify conversion of elevated capital equipment backlog into shipped revenue, and check Q3 Peripheral Vascular backorder clearance milestones.
Trigger: Organic net sales growth between 8.3% and 9.3% YoY and full-year adjusted EPS between $14.95 and $15.10.5
Financial performance within guided corridors affirms the baseline recovery thesis, but current market valuation fairly balances operational compounding against macroeconomic risks.
Mancato
Downgrade the rating; Trim position size toward conservative allocation limits, review hospital capex budget health, and re-underwrite terminal valuation multiples.
Trigger: Organic net sales growth < 8.3% YoY or full-year adjusted EPS < $14.95 with operating margins falling below 19.0%.5
Missing guided ranges would indicate that hospital capex deferrals are materializing, competitive pressures are restricting placements, or operational and cyber remediation costs are lingering, warranting a rating downgrade.
Qualità degli utili
Stryker exhibits high earnings quality supported by disciplined cash conversion, transparent non-GAAP reporting reconciliations, and healthy working capital management. Operating cash flow tracks net income closely, underscoring strong cash conversion across hospital capital equipment and orthopaedic implant deliveries. The spread between GAAP and adjusted diluted earnings per share primarily reflects routine amortization of purchased intangible assets alongside transient structural optimization and cyber recovery charges, rather than aggressive operational accounting adjustments.
Andamento delle stime
Consensus analyst revisions following the Q2 2026 earnings release have remained flat across both revenue and EPS curves. Consensus FY2026 diluted EPS settled at $14.95 (within management's narrowed $14.95-$15.10 guidance range) and FY2027 diluted EPS held steady at $16.66. Consensus revenue estimates for FY2026 of $27.17B and FY2027 of $29.49B align with house baseline expectations.1,5
Metriche da monitorare prima della pubblicazione
01
Metrica:
Full-Year Organic Net Sales Growth Corridor
AttualeDelivered 9.0% organic sales growth in Q2 2026; full-year guidance narrowed to 8.3%-9.3%.
Perché è importante
Validates whether core procedure volumes and hospital capital spending support management's target to grow at the upper tier of medical technology.
Stryker demonstrates high cash flow quality characterized by disciplined capital expenditure and strong conversion. In FY2025, operating cash flow reached $5,044M, which after capital expenditures of $761M yielded free cash flow of $4,283M (an 84.9% free cash flow conversion of operating cash flow). In the first half of 2026, operating cash flow increased 35.3% YoY to $1,842M, supported by working capital improvements following initial cyber incident disruptions. Capex remained modest at $368M in 6M 2026, confirming the asset-light nature of Stryker's ongoing operations.6,7
Stryker's ROIC of 11.45% delivers a positive economic spread of +324 bps above its 8.21% WACC. Operating margin progression from 19.47% in FY2025 toward 21.2% by FY2030 will expand ROIC further as post-incident manufacturing absorption normalizes.
ROIC of 11.45% exceeds computed WACC of 8.21% by 3.24 percentage points.
Exceptional Free Cash Flow Conversion Powered by Low Capital Intensity
FY2025 operating cash flow of $5,044M and capex of $761M produced $4,283M in free cash flow, representing a 3.03% ratio compared to the 4.5% industry benchmark.
Ricavi più recenti25,1 Mld USDCAGR dei ricavi +9,3%
Margine operativo19,5%10 periodi fiscali
Flusso di cassa libero più recente4,3 Mld USDFY2025
Debito netto12,3 Mld USDFY2025
Dettaglio del conto economicoCome la scala aziendale si traduce in utile dichiarato.30 giu 2026
StockMarketAgent.AI
Ricavi6,6 Mld USDCosto del venduto−2,1 Mld USDUtile lordo4,5 Mld USDCosti operativi−2,8 Mld USDReddito operativo1,7 Mld USDVoci non operative e imposte−383 Mln USDUtile netto1,3 Mld USD
Dati della storia finanziaria
Ricavi
6.589.000.000 USD
Costo del venduto
2.091.000.000 USD
Utile lordo
4.498.000.000 USD
Costi operativi
2.839.000.000 USD
Reddito operativo
1.659.000.000 USD
Voci non operative e imposte
-383.000.000 USD
Utile netto
1.276.000.000 USD
Panoramica dello stato patrimonialeCome sono detenute e finanziate le attività dichiarate nel periodo selezionato.
Ponte dei flussi di cassaCome il flusso di cassa operativo è diventato flusso di cassa libero nel FY2025.
StockMarketAgent.AI
Riconciliazione del flusso operativo
Utile netto3,2 Mld USDAmmortamenti e svalutazioni+1,6 Mld USDCompensi basati su azioni+243 Mln USDAltre rettifiche operative−15 Mln USDFlusso di cassa operativo5 Mld USD
Riconciliazione della liquidità iniziale e finale
Liquidità iniziale3,7 Mld USDFlusso di cassa operativo+5 Mld USDFlusso da investimenti−4,9 Mld USDFlusso da finanziamenti+113 Mln USDEffetto dei tassi di cambio+68 Mln USDLiquidità finale4 Mld USD
5 Mld USD − 761 Mln USDFlusso di cassa libero 4,3 Mld USD
Dati del ponte dei flussi di cassa
Utile netto
3.246.000.000 USD
Afflusso operativo
5.059.000.000 USD
Ammortamenti e svalutazioni
1.570.000.000 USD
Compensi basati su azioni
243.000.000 USD
Flusso di cassa operativo
5.044.000.000 USD
Deflusso operativo
15.000.000 USD
Liquidità disponibile
8.877.000.000 USD
Liquidità iniziale
3.652.000.000 USD
Afflusso da finanziamenti
113.000.000 USD
Effetto dei tassi di cambio
68.000.000 USD
Deflusso da investimenti
4.866.000.000 USD
Capex
761.000.000 USD
Altre attività di investimento
4.105.000.000 USD
Liquidità finale
4.011.000.000 USD
Flusso da investimenti
-4.866.000.000 USD
Flusso da finanziamenti
113.000.000 USD
Ricavi per segmento operativoQuota dei ricavi totali per 2025-12-31.
25,1 Mld USDRicavi totali
Ricavi per segmento operativoQuota
Med Surg And Neurotechnology15,6 Mld USD62,3%+15,7% a/a
Orthopaedics9,5 Mld USD37,7%+4,3% a/a
Fonte: SEC EDGAR · Depositato 2026-02-11 · SEC EDGAR
Dati sulla composizione dei ricavi: Ricavi per segmento operativo
Ricavi per segmento operativo
Ricavi
Quota
a/a
Med Surg And Neurotechnology
15,6 Mld USD
62,3%
15,7%
Orthopaedics
9,5 Mld USD
37,7%
4,3%
Ricavi e utiliCome la scala aziendale si traduce in utile dichiarato.
Liquidità e debitoLiquidità disponibile rispetto all’indebitamento totale.
Generazione di cassaFlusso di cassa operativo rispetto al flusso di cassa libero.
RedditivitàEvoluzione dei margini lordo, operativo e netto.
Dati finanziari puntuali utilizzati nell’analisi del 2026-10-22.
Stryker Corporation (SYK) trades at 16.5x forward earnings against a peer median of 15.6x. Its EV/EBITDA of 17.1x compares with a peer median of 13.8x. The comparison uses 4 peers: Boston Scientific Corporation, GE HealthCare Technologies Inc., Edwards Lifesciences Corporation and STERIS plc, as of 2026-10-21 to 2026-10-22.
§10 Settore e cicloEN
Fase del ciclo
Expansion
Industry capital expenditures track at 4.5% of revenue with a capex-to-depreciation ratio of 0.8x, indicating disciplined replacement capex rather than aggressive capacity overexpansion. Stryker's own FY2025 capex of $761M on $25,116M revenue (3.03%) further demonstrates restrained capital intensity. Because adapter data does not supply comprehensive equipment lead times or utilization metrics, the industry cycle view is demand-led and evidence-limited.7
Ciclo rialzista
Robust hospital capex budgets, accelerating migration of joint reconstructions to ASCs, record robotic conversions, and steady procedure volume expansion drive double-digit EPS growth and multiple expansion across large-cap medtech.
Ciclo ribassista
Hospital financial austerity and capex freezes delay robotic placements and bed replacements, while persistent supply chain bottlenecks and elevated interest rates depress industry valuation multiples toward 13x-14x forward earnings.
Trend secolari
Trend
Impatto
Nota
Aging Demographics and Rising Orthopedic Procedure Volumes
positive
Aging global demographics and longer active lifespans drive steady procedural volume growth in knee, hip, and trauma joint replacements, underpinning sustained multi-year demand.
Migration of Joint Reconstruction to Ambulatory Surgery Centers (ASCs)
positive
Surgical procedure migration to outpatient Ambulatory Surgery Centers creates fresh demand for robotic-assisted surgery systems tailored for ASC economics.
Posizionamento
Stryker commands leading global positions in Orthopaedics ($9,469M FY2025 revenue) and MedSurg and Neurotechnology ($15,647M FY2025 revenue). Its dominant Mako robotic surgery footprint, comprehensive operating room equipment catalog, and connected software platforms position the company to outpace broader industry procedural growth and gain market share from fragmented competitors.8
§11 Gestione della posizioneEN
Dimensionamento
3-4%
A Hold rating reflects balanced risk-reward with shares trading at $297.60 (as of 2026-10-21) relative to Fair value of $313.18. While Stryker is a high-conviction compounder, full valuation caps incremental position sizing.
Rischio
Control portfolio exposure through strict position sizing caps, rebalance opportunistically as valuation reaches extreme bands, and maintain diversification across less capital-sensitive healthcare segments.
Tranche di ingresso
Livello
Azione
Perché
Discount to Fair value tranche
Deploy initial incremental capital to establish an initial portfolio tranche.
Represents a >10% discount to our $313.18 fair value midpoint, providing an attractive risk-adjusted margin of safety.
Deep valuation compression tranche
Scale up allocation toward target portfolio weighting.
Stryker offers exceptional structural advantages, an expanding robotic surgery ecosystem, and robust free cash flow conversion, but shares at $297.60 trade near fair value ($313.18), warranting a patient stance for better entry points.4
Value Investor
Hold
With shares trading at $297.60 (as of 2026-10-21) offering an upside of 5.2% to Fair value of $313.18, valuation does not offer an adequate margin of safety relative to prevailing risk-free interest rates.2
Tactical / Momentum Investor
Hold
Post-earnings consensus estimate revisions are flat and guidance ranges are tightly bound, suggesting limited near-term multiple re-rating catalysts until supply chain normalization and Mako order conversion deliver upside surprises.5
§14 Raccomandazione finaleEN
Azione
Mantenere
Stryker Corporation is an elite medical technology compounder with a Narrow economic moat established across robotic orthopedic surgery and hospital infrastructure. However, with shares trading at $297.60 relative to our fair value midpoint of $313.18 (+5.24% implied return), market pricing adequately reflects near-term operational recovery, justifying a Hold rating.4
Investors should retain existing allocations, monitor execution on elevated capital equipment order backlogs and Q3 Peripheral Vascular supply resolution, and await wider valuation discounts before committing fresh capital.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Analyst consensusData as of 2026-10-22 · Published 2026-10-22 · Provider-adjusted · cited for 4 figuresCited in Scenari, Albero decisionale degli utili
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Persistent Cyber Remediation Overhead and Absorption Drag
Continued costs from lost manufacturing absorption, elevated IT cybersecurity spending, and unabsorbed overhead as described by management depress operating margins below 16.5%, reverting toward 2024 levels (16.33%) and industry benchmark (15.5%).5
FV impact
-1.5%
Operating margin 3 points lower throughout
Trigger
Within 18 months
Macro Valuation Compression and Peer Multiple Convergence
Persistent higher interest rates (risk-free rate 5.15%) compress valuation multiples toward peer BSX forward P/E of 13.18x and GEHC forward P/E of 12.98x, derating Stryker from its terminal 18.0x assumption to 14.0x.2,3
FV impact
-6.1%
Terminal multiple 20% lower
Trigger
Within 12 months
Margin contraction below 16.5% signals inability to absorb remediation overhead and persistent fixed-cost deleverage.
Attuale:19.47% in FY2025; 20.6% reported / 24.4% adjusted in 6M 2026
Avviso se< 16.5%
03
Forward Price-to-Earnings Multiple
Multiple compression below 14.0x indicates market derating toward peer medtech medians (BSX 13.18x, GEHC 12.98x) under persistent high interest rates.
Prolonged negative growth past Q4 2026 indicates permanent customer defection and market share loss to competitors rather than transient supply friction.
Attuale:-6.7% YoY in Q2 2026
Avviso seNegative YoY organic growth persisting past Q4 2026
05
Hospital Capital Equipment Order Conversion and Backlog Delivery
Order cancellations or lengthening conversion cycles signal hospital capital spending retrenchment, impairing high-margin capital equipment revenue.
Attuale:Elevated backlog with record Mako sales in Q2 2026
Avviso seNet backlog contraction or order cancellations exceeding 5% YoY
03
Software Integration and Connected Healthcare Ecosystem — Stryker's integrated hospital infrastructure—combining ProCuity connected hospital beds, Vocera clinical communication systems, and Care.ai SmartCare digital workflows—creates a sticky, interconnected clinical IT ecosystem embedded across healthcare networks.
Discounted forecast-period cash flows (43,86 USD) plus discounted terminal value (172 USD) minus signed per current share (31,96 USD) equals the 184 USD lens value shown above. Negative net debt is , so subtracting it raises value.
FY2027 revenue of $29.49B and adjusted EPS of $16.66.1
Operating margin expands from 19.5% in FY2026 to 21.2% in FY2030.
Terminal exit P/E multiple of 18.0x and perpetual growth rate of 3.0%.
Stryker executes within its guided organic sales growth corridors, transitioning to steady high-single-digit revenue expansion through FY2030 supported by resilient reconstructive procedure volumes and steady operating margin progression.5
Adjusted operating margin expanded year-over-year in the second quarter, demonstrating sequential recovery as manufacturing absorption normalizes.
Perché è importante
Confirms that manufacturing fixed-cost absorption and efficiency programs are offsetting residual cyber remediation expenses.5
03
Metrica:
Peripheral Vascular Backorder Normalization
AttualeU.S. organic sales declined 6.7% in Q2 2026; management expects backorders to reach manageable levels by end of Q3.
Perché è importante
Tests the speed of supply chain resolution and verifies customer retention following acute manufacturing disruptions.5
04
Metrica:
Mako Robotic Placements and ASC Adoption
AttualeAchieved record monthly Mako sales in Q2 2026 with an elevated placement backlog.
Perché è importante
Directly drives proprietary implant pull-through in knees and hips across outpatient surgical facilities.5
05
Metrica:
Executive Leadership Succession Execution
AttualeSpencer Stiles appointed Chief Executive Officer effective in early 2027, with Kevin Lobo transitioning to Executive Chair.
Perché è importante
Maintains continuity of Stryker's acquisition playbook, organizational culture, and operating model.
Stryker maintains a disciplined, shareholder-friendly capital allocation strategy focused on programmatic tuck-in acquisitions, dividend growth, and selective share repurchases. Under CEO Lobo, the company completed over 60 acquisitions, including transformative transactions such as Mako, Wright Medical, Vocera, and Inari. In the first six months of 2026, Stryker invested $459M in acquisitions, paid $674M in dividends, and executed $750M in net debt payments. Total debt of $15,446M against a market capitalization of $114,151M reflects a modest 11.92% debt weight, preserving ample borrowing headroom, while approximately $1 billion in authorized repurchase capacity remains available for opportunistic share buybacks.
Restrained capital intensity generates abundant surplus cash flow, enabling continuous tuck-in M&A and dividend increases without stretching the balance sheet.
Operating margins rebounded from 16.33% in FY2024 to 19.47% in FY2025, and adjusted operating margin expanded 170 bps YoY to 27.4% in Q2 2026.
Fixed-cost recovery from manufacturing shutdowns and tapering cyber IT overhead create a reliable runway to reach 21.2% operating margins by FY2030.
Diversified Business Mix Insulates Enterprise Growth
In Q2 2026, MedSurg and Neurotechnology delivered 9.7% reported growth ($3,625M) while Orthopaedics delivered 9.1% reported growth ($2,964M).
Broad procedural and equipment diversification insulates enterprise revenue from isolated segment disruptions, such as the temporary -6.7% decline in U.S. Peripheral Vascular sales.
Hospital Workflow Automation and Healthcare IT Connectivity
positive
Hospitals increasingly adopt connected bed systems (ProCuity) and clinical communication platforms (Vocera, Care.ai) to enhance nurse efficiency, patient safety, and workflow automation.
Regulatory Compliance and Component Supply Chain Constraints
neutral
Complex regulatory requirements including European Medical Device Regulation (EU MDR) and specialized medical supply chain vulnerabilities introduce localized backorders and compliance friction.
Re-assess operating leverage trajectory and review position for trimming.
Peripheral Vascular U.S. Organic Growth
Negative YoY organic growth persisting into Q4 2026
Reduce vascular growth assumptions and evaluate competitive market share losses.5
